| Revenue growth | FY26 up 14% YoY; Q4FY26 up 19% YoY. |
|---|---|
| Margins | H1FY27 margins temporarily impacted; H2FY27 recovery to 17-18%. |
| Demand visibility | Strong growth in Ruby-Fill; biotech demand expected to improve. |
| Management confidence | High confidence in regulatory path for MIBG and pipeline acceleration. |
Growth
FY26 Revenue up 14% to ₹8,280 Cr; EBITDA up 8% to ₹1,326 Cr; Normalized PAT up 7% to ₹4,422 Cr.
Outlook
Guided H2FY27 EBITDA margins of 17-18%. Committed to net debt zero by 2030. Commencing commercial production on Line 3 late FY2027.
Risks
Short-term margin pressure in H1FY27 due to SPECT product supply shortages and lower production at CMO Montreal.
Earnings Call filed with BSE, NSE: JUBLPHARMA. Summary written with AI assistance from the document.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹975.00
- Market cap
- ₹15,530 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 44.1×Sector 47.4×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Business Update
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Legal & Regulatory
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
- Value
- ₹87.31 Cr
Jubilant Pharmova Legal & Regulatory
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
- Value
- ₹105.5 Cr
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova Production Started
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.